USSTOCK.TODAY
Pre-Market
Log in Sign up

AbCellera Biologics Inc. Transitions to Late-Stage Clinical Trials and Raises $200 Million

The Motley Fool +1 · ·by G4L

ABCL
ABCL AbCellera Biologics Inc
$12.50 +5.22%
View chart & analysis →
  1. 1AbCellera Biologics Inc. reported a transition to late-stage clinical development in Q3 2026.
  2. 2AbCellera Biologics Inc. completed a $200 million capital raise in Q3 2026.
  3. 3AbCellera Biologics Inc. recorded a net loss of approximately $41 million in Q3 2026.

So what's the key point?

AbCellera Biologics Inc. is moving up its drug development stages and has raised $200 million in funding. However, the company is spending money and recorded a loss of $41 million.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Apcelleera shares surge up to 41% on mid-stage trial results for facial-flushing treatment Bloomberg · Aug 10Apcelera shares surge 22% on positive Phase 2 results for ABCL635 InvestorsHub +1 · Aug 10Xenon Pharmaceuticals Files for Approval and Advances Azetucalnor Clinical Trials The Motley Fool +1 · 6h ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news